13.96
-0.59 (-4.05%)
News Mood
-
Omeros (OMER) Surpasses Q3 Earnings and Revenue Estimates
3 days ago, 3:15PM
-
Omeros (OMER) Q3 2026 Earnings Call Transcript
2 days ago, 9:48AM
-
Omeros (OMER) Just Gave Investors Another Reason to Sell
yesterday, 12:11AM
-
OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares
2 days ago, 11:12AM
-
Omeros falls 10% despite revenue beat
3 days ago, 3:50PM
AIStockmoo Score
| Value 30% | -4.6 |
| Earns below its cost of capital. Returns on capital falling. info | |
| Weak profitability. Thin short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | -1.3 |
| Uptrend over the past year. Far below its 52-week high. info | |
| No clear trend: the price is moving around its moving averages. It has dropped well below them. Volume is heavier on down days. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | -0.3 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly negative. info | |
| Holdings' Sentiment info | NA |
| Smart Money 20% | 3.4 |
| Institutions net +5.23% of shares in their latest 13F filings: 118 holders increased, 74 decreased (quarter to 30 Sep 2026). info | |
| Short interest +0.6% from 31 Aug to 30 Oct 2026, 9.6 days to cover (FINRA). info | |
| Insider Activity info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Below its medium-term trend line. info | |
| Price is near its 52-week average. Up over 5 years. info | |
| Short-term momentum falling. info | |
| Price is near support. Levels trending down. info | |
| Final Score | -1.28 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Omeros Corporation | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| OMER | - | - | - | - | -1.3 |
| HLVX | 103 M | - | - | 0.710 | 0.0 |
| MEIP | 49 M | - | - | - | 0.0 |
| SONN | 33 M | - | - | 2.07 | -1.4 |
| INAB | - | - | - | 0.570 | -2.5 |
| ANIX | - | - | - | 6.26 | -1.6 |
Select this tab to load the latest available analysis.
|
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.40% |
| % Held by Institutions | 47.30% |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 57.08%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 118 | 7,503,141 |
| Decreased | 74 | 5,004,246 |
| New | 46 | 3,662,204 |
| Sold out | 24 | 2,294,472 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 12,833,757 | 9.6 |
| 15 Oct 2026 | 11,428,767 | 12.2 |
| 30 Sep 2026 | 11,382,531 | 6.9 |
| 15 Sep 2026 | 12,491,576 | 9.3 |
| 31 Aug 2026 | 12,758,406 | 7.3 |
| 14 Aug 2026 | 14,639,133 | 4.9 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 18 Nov 2026 | Yahoo Finance |
Omeros (OMER) Just Gave Investors Another Reason to Sell
Omeros Corp. (NASDAQ:OMER) is one of the 10 Stocks Investors Are Fleeing. Omeros Corp. fell 16.55 percent on Tuesday to close at $13.92 apiece, after incurring wider losses in the third quarter of the year. In an updated report, the company said that its net loss fell by 85 percent to $57.3 million… |
| 17 Nov 2026 | Yahoo Finance |
OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares
CEO Demopulos said the company is now shifting its near-term regulatory strategy outside the European Union. |
| 17 Nov 2026 | Yahoo Finance |
Omeros (OMER) Q3 2026 Earnings Call Transcript
YARTEMLEA gained hospital access as gross product revenue rose 30% this quarter. |
| 17 Nov 2026 | Yahoo Finance |
Omeros Corporation Q3 2026 Earnings Call Summary
Moby summary of Omeros Corporation's Q3 2026 earnings call… |
| 17 Nov 2026 | Yahoo Finance |
Omeros Corp (OMER) Q3 2026 Earnings Call Highlights: YARTEMLEA Sales Surge 30% as Operating ...
Omeros Corp (OMER) posted $41.8 million in YARTEMLEA gross sales and $13.3 million in positive operating cash flow, though a $62 million non-cash charge drove a GAAP net loss. |
| 16 Nov 2026 | Yahoo Finance |
Omeros Q3 Earnings Call Highlights
Omeros (NASDAQ:OMER) reported higher third-quarter sales of its transplant complication treatment YARTEMLEA and a second consecutive quarter of positive operating cash flow, while a non-cash adjustment tied to its convertible notes pushed the company to a net loss. YARTEMLEA generated $35.9 million… |
| 16 Nov 2026 | Yahoo Finance |
Omeros falls 10% despite revenue beat
Investing.com -- Omeros Corporation (NASDAQ:OMER) reported third-quarter results that exceeded analyst expectations for both revenue and earnings, but shares tumbled 10% in after-hours trading Monday as the company posted a widened GAAP net loss. |
| 16 Nov 2026 | Yahoo Finance |
Omeros (OMER) Surpasses Q3 Earnings and Revenue Estimates
Omeros (OMER) delivered earnings and revenue surprises of +220.00% and +16.29%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 16 Nov 2026 | Yahoo Finance |
Omeros: Q3 Earnings Snapshot
SEATTLE (AP) — SEATTLE (AP) — Omeros Corporation (OMER) on Monday reported a loss of $57.On a per-share basis, the Seattle-based company said it had a loss of 79 cents. |
| 16 Nov 2026 | Yahoo Finance |
Omeros Corporation Reports Third Quarter 2026 Financial Results
SEATTLE, November 16, 2026--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2026, which include:… |
| 12 Nov 2026 | Yahoo Finance |
Omeros (OMER) Stock May Be Undervalued After Investor Fraud Probe
Omeros has been on a dramatic multi year run, yet recent headlines and price swings leave a straightforward question for investors who focus on fundamentals. Is the current share price properly supported by what the business is earning today and what those earnings suggest about the future? Over… |
| 10 Nov 2026 | Yahoo Finance |
Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026
SEATTLE, November 10, 2026--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the third quarter of 2026 on Monday, November 16, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time… |
| 16 Oct 2026 | Yahoo Finance |
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index down 0.1% and the… |
| 16 Oct 2026 | Yahoo Finance |
Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion on Omeros’ marketing authorization application for narsoplimab, sold as Yartemlea in the United States, the company said on Friday. |
| 16 Oct 2026 | Yahoo Finance |
Sector Update: Healthcare Stocks Mixed Friday Afternoon
Healthcare stocks were mixed Friday afternoon, with the NYSE Healthcare Index up 0.1% and the State… |
| 16 Oct 2026 | Yahoo Finance |
Omeros Shares Fall 4% as European Regulators Uphold Negative Opinion on Narsoplimab
Omeros Corporation (NASDAQ:OMER) shares declined 4% in Friday morning trading after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) maintained its negative opinion on the company’s marketing authorisation application for narsoplimab. The decision followed… |
| 16 Oct 2026 | Yahoo Finance |
Omeros shares slide following European regulatory setback for Narsoplimab
Investing.com -- Shares of Omeros Corporation (NASDAQ: OMER) retreated 4% in Friday morning trading after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) maintained a negative opinion on the marketing authorization application for its drug, narsoplimab. |
| 16 Oct 2026 | Yahoo Finance |
Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months
European regulators rejected Omeros’ application for Narsoplimab, which is used to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy. |
| 16 Oct 2026 | Yahoo Finance |
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
SEATTLE, October 16, 2026--Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the company’s marketing authorization application (MAA) for narsoplimab for the treatment… |
| 23 Sep 2026 | Yahoo Finance |
Dow Jones Futures Fall After Nasdaq Hits New High; Sandisk, Micron Trigger Buy Signals
The Nasdaq hit a new high with memory giants Sandisk and Micron flashing buy signals. But financials are struggling. |
| 22 Sep 2026 | Yahoo Finance |
NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?
Natera’s Signatera test secured a key regulatory approval, while Cantor raised its sales expectations for Omeros’ lead drug, Yartemlea. |
| 28 Aug 2026 | Yahoo Finance |
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out. |
| 25 Aug 2026 | Yahoo Finance |
Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react? |
| 19 Aug 2026 | Yahoo Finance |
Omeros (OMER) Q2 2026 Earnings Call Transcript
Yartemlia generated $32.2M in gross sales during its first full quarter on market. |
| Show more | ||
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |